REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai Peptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) DoaiPeptide Containing (e.g., Protein, Peptones, Fibrinogen, Etc.) Doai patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.03/01/07 - 20070049514 - Resonance modulator for diagnosis and therapy A method and device are disclosed for monitoring and/or altering an immune function. The method uses a resonance modulating compound as a coupling agent that is capable of interacting with the immune system to monitor or stimulate immune function. The resonance modulator has electromagnetic properties that attract immune cells to ... 02/22/07 - 20070042936 - Multivalent inhibitors of serum amyloid p component Novel glycerol cyclic pyruvate derivates were prepared and demonstrated to inhibit the binding of an immobilized D-proline derivative to serum amyloid P component (SAP) have been prepared. As such, the compounds of the invention are useful for treating amyloidosis and diseases associated with amyloidosis, for example Alzheimer&supl;s disease and maturity ... 02/15/07 - 20070037734 - Process for the purification of il-18 binding protein The invention relates to a process for the purification of IL-18 binding protein (IL-18BP) from a fluid comprising hydrophobic charge-induction chromatography. ... 02/08/07 - 20070032403 - Crystal structure of the itk kinase domain Disclosed are polypeptides encoding the ITK kinase domain and nucleic acids encoding such polypeptides, crystal structures of various polypeptide-ligand complexes comprising the ITK kinase domain bound to a ligand, methods of producing the aforementioned polypeptides and nucleic acids which encode them and methods of producing crystal structures of the aforementioned ... 01/25/07 - 20070021324 - Process for preparation of mixtures of polypeptides using purified hydrobromic acid The subject invention provides an improved process for obtaining a mixture of polypeptides having nonuniform amino acid sequences, where each polypeptide consists essentially of alanine, glutamic acid, tyrosine and lysine where the resulting mixture of polypeptides comprises less than 0.3% brominated tyrosine and less than 1000 ppm metal ion impurities. ... 01/25/07 - 20070021323 - Use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer in an amount sufficient to prevent or treat said cancer, wherein said cancer is susceptible to prevention or treatment by said nitroxide or prodrug thereof. Also provided is a composition for use in the method. ... 01/25/07 - 20070021322 - Selective resonance of chemical structures Chemical compositions may be selectively or preferentially excited by the application of scores comprising a series of energy inputs. ... 01/25/07 - 20070021321 - Method of screening drug with the use of 67 kda laminin receptor and drug obtained thereby It is intended to provide a novel method of screening a drug with the use of a 67 kDa laminin receptor and a drug obtained thereby. A method of screening a drug having an effect on inhibiting cell proliferation, an angiogenesis inhibitory effect, an effect of inhibiting cancer cell metastasis, ... 01/18/07 - 20070015686 - Dietary supplement for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells A dietary supplement and method for enhancing skeletal muscle mass, decreasing muscle protein degradation, downregulation of muscle catabolism pathways, and decreasing catabolism of muscle cells an individual, the supplement comprising at least source of Creatine or derivatives thereof, a source of Gypenosides or Phanoside or derivatives thereof, Creatinol-O-phosphate, and a ... 01/18/07 - 20070015685 - Bone cement compositions and the like comprising an rnaiii-inhibiting peptide RNAIII-inhibiting peptide (RIP) advantageously treats or reduces the risk of biofilm formation on implanted bone cement, thus reducing the possibility of sustained chemotherapy, hospitalization, or surgical removal of the bone cement. Unlike antibiotics, RIP eradicates biofilms without inducing resistant bacterial strains, making RIP particularly advantageous in this application. Biodegradable compositions ... 01/11/07 - 20070010422 - Compounds and compositions for delivering active agents Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... 12/28/06 - 20060293218 - Salicylate therapeutic compound and process for controlled delivery thereof A therapeutic composition includes a salicylate administering concert with at least one salicylate excretion compound of a glycine salicylate conjugate and a gluconoride salicylate conjugate. A therapeutic composition is provided that has an extended excretion half-life for a salicylate that includes the administration of the salicylate in concert with an ... 12/28/06 - 20060293217 - Pharmaceutical formulations for sustained release Sustained delivery pharmaceutical compositions comprising a solid ionic complex of a pharmaceutically active compound and an ionic macromolecule are provided by the present invention. The pharmaceutical compositions of the invention allow for loading of high concentrations of pharmaceutically active compounds and for delivery of a pharmaceutically active compound for prolonged ... 12/28/06 - 20060293216 - Pharmaceutical compositions comprising an active agent and chitosan for sustained drug release or mucoadhesion The invention provides a pharmaceutical composition comprising a physiologically active agent and a release sustaining or mucoadhesive agent, characterized in that said release sustaining or mucoadhesive agent comprises a chitosan having a FA of from 0.25 to 0.80. ... 12/21/06 - 20060287220 - Water soluble paclitaxel prodrugs Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include ... 12/14/06 - 20060281668 - Vascular disease therapies The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided. ... 12/14/06 - 20060281667 - Cardiovascular disease therapies The present invention relates to methods and agents for treating impaired vascular and cardiac function. Methods and agents for treating various physiological and pathological features associated with vascular dysfunction and cardiac dysfunction are also provided. ... 12/07/06 - 20060276373 - Neuroprotective complex for treatment of cerebral ischemia and injury The invention provides a pharmaceutical composition useful in treating cerebral ischemia and traumatic cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, ... 12/07/06 - 20060276372 - Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders A method and system used for treating proliferative disorders using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The method and system may be used for chemoprevention and/or chemotherapy. The method and system may induce apoptosis in target cells, tissues, and/or organs. The analog, derivative, or intermediate may be administered to a ... 11/30/06 - 20060270590 - Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof Administering water-soluble or dispersible synthetic analogs or derivatives of astaxanthin, lutein, zeaxanthin, or lycophyll and/or other carotenoids to a subject may reduce some of the adverse effects of inflammation in a body organ or tissue. The analogs or derivatives may be incorporated into pharmaceutical, over-the-counter, or nutraceutical preparations. Administration of ... 11/30/06 - 20060270589 - Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of visual disabilities A method and system used for treating visual disabilities using carotenoids, carotenoid analogs, and/or carotenoid derivatives. The analog, derivative, or intermediate may be administered such that a subject's risk of experiencing diseases associated with visual disabilities may be thereby reduced. Analogs or derivatives of carotenoids may include substituents including for ... 11/23/06 - 20060264356 - Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents Cyanophenoxy carboxylic acid compounds and compositions for the delivery of active agents are provided. Methods of administration, treatment of disease and preparation are provided as well. ... 11/23/06 - 20060264355 - Separating material The present invention provides a separating material producable by a) providing a solid substrate, having amino-functional groups coupled to the substrate surface, b) covalently coupling of the amino-functional groups with a thermally labile radical initiator, c) contacting the substrate surface with a solution of polymerizable monomers under conditions, where thermally ... 11/23/06 - 20060264354 - Cop 1 for treatment of inflammatory bowel diseases The present invention relates to the use of Copolymer 1 (glatiramer acetate), a Copolymer 1-related polypeptide, or a Copolymer 1-related peptide, for the treatment of inflammatory bowel diseases such as Crohn's disease and ulcerative colitis. ... 11/23/06 - 20060264353 - Prostaglandin f2alpha analogs and their use in combination with antimicrobial proteins for the treatment of glaucoma and intraocular hypertension An ophthalmic formulation for the treatment of glaucoma and intraocular pressure with a prostaglandin compound of the F-series (PGF), and particularly a prodrug form of a PGF2α analog, such as an ester, amide, or internal lactone, wherein preservative is an antimicrobial peptide, such as lactoferrin. In particularly preferred embodiments, the ... 11/16/06 - 20060258560 - Dry tissue sealant compositions A dry tissue sealant composition is provided, wherein composition includes a matrix scaffold coated with an adhesive layer, which is adherent to a tissue only upon contact with an aqueous solution such as blood or tissue fluid. Also provided are methods of making and using such a dry tissue sealant. ... 11/02/06 - 20060247152 - Substituted fullerenes and their use as inhibitors of cell death This patent discloses the use of water-soluble substituted fullerenes as inhibitors of cell death. The substituted fullerenes comprise a fullerene core (Cn) and at least one of: (i) from 1 to 6 (>CX1X2) groups bonded to the fullerene core; (ii) from 1 to 18 -X3 groups bonded to the fullerene ... 10/26/06 - 20060241017 - Novel compounds with high therapeutic index The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced ... 10/26/06 - 20060241016 - Extraction process A process for isolating low molecular weight (“LMW”) peptides from tissue in situ comprising the steps: a) homogenizing the tissue; b) mixing the homogenized tissue with an organic solvent to form a fully-wetted slurry; c) standing or agitating the slurry to denature the proteins in situ within the tissue; d) ... 10/26/06 - 20060241015 - Cancer genes The present invention relates to all facets of novel polynucleotides, the polypeptides they encode, antibodies and specific binding partners thereto, and their applications to research, diagnosis, drug discovery, therapy, clinical medicine, forensic science and medicine, etc. The polynucleotides are differentially expressed in prostate and breast cancers and are therefore useful ... 10/19/06 - 20060234912 - Methods for modulating neuronal responses The invention provides, in part, methods and reagents for modulating neuronal apoptosis and for modulating synaptic plasticity. ... 10/19/06 - 20060234911 - Method of reversing epithelial mesenchymal transition A method of reversing epithelial mesenchymal transition, comprising the step of treating a fibrotic disease patient or cancer disease patient with an amount of kinase inhibitor capable of reversing EMT, wherein the kinase inhibitor comprises a TGF-βI kinase inhibitor and a Rho kinase inhibitor or a TGF-βI inhibitor and a ... 10/19/06 - 20060234910 - Methods for the treatment of insulin resistance and disease states characterized by insulin resistance The MINOR and TR3 genes are disclosed to be insulin responsive genes differentially expressed as a function of insulin resistance and Type 2 Diabetes in humans and a variety of well characterized animal models. The present disclosure shows that MINOR and TR3 have a functional role in insulin resistance. Therefore, ... 10/19/06 - 20060234909 - Compositions and methods for increasing drug efficiency wherein D is a drug moiety; L, which may or may not be present, is a non-releasing linker moiety; and S is a substrate for a protein or lipid kinase that is overexpressed, overactive or exhibits undesired activity in a target system. ... 10/19/06 - 20060234908 - Methods for improving the structure and function of arterioles The present invention relates to the unexpected finding that vessels smaller than even the smallest arteries (i.e. arterioles) thicken, become dysfunctional and cause end organ damage to tissues as diverse as the brain and the kidney. This invention provides a method to improve the structure and function of arterioles and ... 10/19/06 - 20060234907 - Albumin solution and process for the production thereof (c) optionally one or more stabilizers selected from the group of sugars, amino acids and sugar alcohols are added, with the proviso that no indole stabilizer and no C6-C10 fatty acid is employed as said stabilizer, whereupon (d) said second albumin solution to which a stabilizer has optionally been added ... 10/19/06 - 20060234906 - Structure of a complex of retinoblastoma protein bound to e2f, and uses thereof The present invention provides the crystal structure of pRb/E2F(409-426) as well as uses of the structure in identifying agents which modulate the binding between pRb and E2F and/or a pRb/E2F(409-426) complex, and thus are useful as pharmaceutical agents in the prevention or treatment of proliferative diseases. ... 10/19/06 - 20060234905 - Method of stimulating growth and resistance to diseases of aquatic organisms The invention is related with the chemical synthesis for increase the growth rate in marketable fish and crustacean The aim of this invention is supply GHRP-6 to induce directly or indirectly the release of growthing hormone or like, to produce the increase of circulating growthing hormone level in the blood ... 10/12/06 - 20060229234 - Peptide factor The present invention relates to use of oxidised thymosin β4 in therapy, more particularly in the treatment of diseases or conditions associated with an inflammatory response or septic shock. The present invention also provides pharmaceutical formulations comprising oxidised thymosin β4 together with a suitable excipient. ... 10/12/06 - 20060229233 - Compositions and methods for treating neurological disorders Compositions useful for treating neurological disorders including neurodegenerative disorders associated with deleterious protein aggregation, aberrant protein folding, such as brain amylogenic diseases, and/or neurodegenerative autoimmune disorders are described. Methods of using said compositions also are described. In particular, methods to treat a neurodegenerative disorder such as Alzheimer's disease and a ... 10/05/06 - 20060223741 - Method of treatment or prophylaxis The present invention is directed to methods and agents that are useful in the prevention and amelioration of signs and symptoms associated with neuropathic conditions. More particularly, the present invention discloses the use of angiotensin II receptor 2 (AT2 receptor) antagonists for the treatment, prophylaxis, reversal and/or symptomatic relief of ... 10/05/06 - 20060223740 - Absorption enhancers such as e.g. bht, bha or propyl gallate The invention provides a pharmaceutical composition comprising a mixture of (a) an active macromolecular principle, and (b) an aromatic alcohol absorption enhancer chosen from butylated hydroxy toluene, butylated hydroxy anisole and analogues and derivatives thereof, wherein the aromatic alcohol absorption enhancer is present in an amount by weight greater than ... 09/28/06 - 20060217289 - Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides Disclosed herein are non-natural amino acids and polypeptides that include at least one non-natural amino acid, and methods for making such non-natural amino acids and polypeptides. The non-natural amino acids, by themselves or as a part of a polypeptide, can include a wide range of possible functionalities, but typical have ... 09/21/06 - 20060211600 - Stem cell-derived factors for treating pathologic conditions Compositions and methods for cellular and tissue protection, repair, and regeneration are described. Mesenchymal cell-derived paracrine factors confer a therapeutic benefit to a variety of injured, compromised or diseased tissues such as myocardial tissue. ... 09/07/06 - 20060199758 - Antimicrobial surfaces V+2 represents a doubly positively charged moiety having the formula —+NR2-T-NR2+—, or 1,4-diazoniabicyclo[2.2.2]octane; T represents a saturated or unsaturated straight-chain hydrocarbon having 1-24 carbon atoms; R represents a saturated or unsaturated hydrocarbon group having 1-24 carbon atoms; phenyl; or benzyl; W represents a saturated or unsaturated straight-chain hydrocarbon having 10-24 ... 08/31/06 - 20060194713 - Methods for treating delirium using glucocorticoid receptor-specific antagonists This invention generally pertains to the field of psychiatry. In particular, this invention pertains to the discovery that agents which inhibit the binding of cortisol to its receptors can be used in methods for treating delirium. Mifepristone, a potent specific glucocorticoid receptor antagonist, can be used in these methods. The ... 08/24/06 - 20060189511 - Method for cytoprotection through mdm2 and hdm2 inhibition The present invention is directed to a method of protecting one or more cells from programmed cytotoxic cell death by contacting the cells with a cytoprotective amount of an MDM2 and/or HDM2 inhibitor. The cytoprotective amount of inhibitor is typically used as a pulsed administration. Useful inhibitors include a class ... 08/17/06 - 20060183665 - Modulators of the potassium channels twik-1, task-1 gorl1. sk2 pr pcn1, used to treat arrhythmia, coronary heat disease or hypertension The invention relates to the use of modulators of the potassium channels TWIK-1, TASK-1, GIRK1 SK2 and PCN1 for producing a medicament for the treatment and/or prophylaxis of cardiac dysrhythmias (arrhythmias), coronary heart disease, and hypertension. ... 08/17/06 - 20060183664 - Pharmaceutical composition for delayed hypersensitivity The present invention provides a pharmaceutical composition by a novel action mechanism without serious side effects for delayed hypersensitivity and a screening method of the same. The invention also provides a novel assay method of inhibitors/suppressive agents of PAR-2. The invention relates to a pharmaceutical composition for delayed hypersensitivity containing ... 08/10/06 - 20060178295 - Steroid conjugates, preparation thereof and the use thereof Conjugates comprising one or more steroids conjugated with one or more mammalian proteins are disclosed. The conjugates are useful for diagnosis or treatment of solid cancer and hematological malignancies. Further the conjugates exhibit a synergistic action together with a cytoskeleton-acting drug such as Taxol®, which enable the treatment of cancers ... 08/10/06 - 20060178294 - Cell permeabilization and stabilization reagent and method of use A cell permeabilization and stabilization reagent and method of use are disclosed. The reagent contains a N-acyl sarcosine or a salt thereof, a pH adjusting agent to adjust pH of the reagent in a range from about 4 to about 6; and an aqueous medium; the reagent having a low ... 08/10/06 - 20060178293 - Cardiotonic polypeptides A polypeptide which has a positive inotropic effect on cultured cardiomyocytes and is non-toxic to mammals. The polypeptide may be isolated from Buthinae scorpion venom. Also disclosed is a pharmaceutical composition comprising the polypeptide and a DNA molecule encoding the polypeptide. ... 08/10/06 - 20060178292 - Methods and compositions of ecdysozoan molt inhibition In general, this invention relates to nucleic acid and amino acid sequences involved in molting and the use of these sequences as targets for the development of compounds that disrupt Ecdysozoan molting, and are useful as insecticides, nematicides, and anti-parasitic agents. ... 08/03/06 - 20060172922 - Methods for combating ischemic injury to epithelial organ A method for enhancing recovery by epithelial cells from ischemia by targeting distinct lesions. The method comprises inhibiting internalization of intercellular junctions, E-cadherin, occludin or other membrane proteins; promoting reuse of preexisting components by targeting for activation specific signaling events during short-term ischemia; inhibiting degradation of E-cadherin or other key ... 08/03/06 - 20060172921 - Method for identifying active anti-apoptosis compounds i) cells which express both CD47 and the integrin αvβ3 are cultured, ii) the cells are caused to produce an apoptosis-inducing substance, and/or a substance or substances which induces/induce apoptosis is/are added, iii) the test substance is added, and iv) the apoptosis rate is measured, and to the substances which ... 08/03/06 - 20060172920 - Oxidised lipids as reversal agents for boronic acid drugs The use of a lipid in oxidised form for the manufacture of a medicament for therapeutically neutralising (i.e. reducing or substantially destroying the activity of) an organoboronate drug. The lipid may be an HDL hydroperoxide. The drug may be TRI 50c or a salt or prodrug thereof. ... 08/03/06 - 20060172919 - Inhibition of angiogenesis and destruction of angiogenic vessels by apolipoprotein a-i and high density lipoprotein Apolipoprotein A-I-rich Lhigh-density Lipoprotein 2 (HDL2) and Apolipoprotein A-I (ApoA-I) was discovered to inhibit angiogenesis in an in vitro human angiogenesis model, the human placental vein angiogenesis model. Apolipoprotein A-I was able to destroy a pre-existing angiogenic response as well as prevent the development of new vessels. Application of Apolipoprotein ... 08/03/06 - 20060172918 - Composite biomaterials This invention provides novel composite biomaterials having excellent bioadaptability and bone inductivity and a process for producing the same. The composite biomaterials comprise hydroxyapatite, collagen, and alginate and have microporous structures in which the c-axis of the hydroxyapatite is oriented along the collagen fibers. ... 07/27/06 - 20060166858 - Bile-acid conjugates providing for sustained systemic concentration of drugs This invention is directed to compounds that provide for sustained systemic concentrations of therapeutic or prophylactic agents following administration to animals. This invention is also directed to pharmaceutical compositions including and methods using such compounds. ... 07/20/06 - 20060160721 - Method of plasma lipidation to prevent, inhibit and/or reverse atherosclerosis The present invention relates to a composition comprising a detergent that can alter the activity of a lipoprotein. Additional aspects include the composition comprising a phospholipid, and the use of the compositions to treat and/or prevent cardiovascular diseases. ... 07/20/06 - 20060160720 - Protein stabilization in solution Provided are storage containers for proteinaceous pharmaceutical compositions which are characterized in, among other things, comprising (i) a wall portion, wherein an inner wall material thereof is selected from silica-coated glass, silicone-coated glass, polymers of non-cyclic olefins, cycloolefin polymers and cycloolefin/linear olefin copolymers and (ii) one or more closure portions ... 07/13/06 - 20060154852 - Beta sheet tapes ribbons in tissue engineering There is described a material comprising ribbons, fibrils or fibres characterised in that each of the ribbons, fibrils or fibres have an antiparallel arrangement of peptides in a beta-sheet-tape-like substructure. ... 07/06/06 - 20060148675 - Methods of reducing angiogenesis The present invention provides methods of reducing angiogenesis in an individual. The methods generally involve administering to the individual an effective amount of a nicotinic acetyl choline receptor antagonist. The methods are useful to treat conditions associated with or resulting from angiogenesis, particularly pathological angiogenesis. The invention further provides methods ... 07/06/06 - 20060148674 - Therapeutic composition An anti-mitotic composition with a therapeutic index greater than 1.1, a clonogenic survival rate of less than 0.1 percent, and a binding affinity index for a class II, a class III, or a class V beta tubulin isotype of at least about 1.1. ... 06/29/06 - 20060142180 - Cholinergic modulation of microglial activation via alpha-7 nicotinic receptors Novel therapeutic targets in the treatment of neuroimmunological and neurodegenerative disorders. Accordingly, methods of treating a neurodegenerative disorder in a patient, as well as inhibiting the release of a proinflammatory cytokine, comprising the step of contacting a target cell with a therapeutically effective amount of a cholinergic agonist, such as ... 06/29/06 - 20060142179 - 4-aminopyridine and a pharmaceutical composition for treatment of neuronal disorders where R1 and R2 are each independently H or a C1-C4 hydrocarbon; R3 is H, and R4 is a moiety capable of crossing the blood brain barrier selected from the group consisting of: an amino acid, a peptide, transferrin, gluconate, lactate, citrate, malate, fumarate, benzoate, salicylate, pyruvate and propionate. The ... 06/29/06 - 20060142178 - Method of treating cancer The present invention is directed to a method of treating cancer which comprises administration of a compound which selectively inhibits the activity of one or two of the isoforms of Akt, a serine/threonine protein kinase. The invention is particularly directed to the method wherein the compound is dependent on the ... 06/22/06 - 20060135406 - Compositions and methods for treating pathologies that necessitate suppression of gastric acid secretion The present invention is related to novel oral compositions comprising an irreversible gastric H+/K+-ATPase proton pump inhibitor (PPI) as a gastric acid secretion inhibitor, pentagastrin (PG) or a PG analogue as an activator of parietal cells in the gastric lumen. In a preferred embodiment, the composition further comprises at least ... 06/22/06 - 20060135405 - Process for producing sterile suspensions of slightly soluble basic peptide complexes, sterile suspensions of slightly soluble basic peptide complexes, pharmaceutical formulations containing them, and the use thereof as medicaments The present invention provides a novel process for producing sterile suspensions of slightly soluble basic peptide complexes. The present invention further provides a novel process for producing sterile lyophilizates of slightly soluble basic peptide complexes. In addition, a novel process for producing sterile suspensions suitable for the parenteral administration of ... 06/22/06 - 20060135404 - Water soluble paclitaxel derivatives Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as poly-glutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include ... 06/22/06 - 20060135403 - Therapeutic formulations for the treatment of beta-amyloid related diseases The method is used for preventing or treating an amyloid-β related disease in a subject. The method comprises administering to a subject in need thereof an effective amount of a first agent that prevents or treats amyloid-β related disease, and a second agent that is (i) a peptide or peptidomimetic ... 06/22/06 - 20060135402 - Oral administration of calcitonin Disclosed is a particular method of orally administering pharmaceutical compositions comprising calcitonin in combination with oral delivery agents, prior to the consumption of food in humans, and a method of treatment of disorders responsive to the action of calcitonin employing such method of administration; also oral calcitonin pharmaceutical compositions with ... 06/22/06 - 20060135401 - Novel method of selecting immunosuppressant having little thrombocytopenic effect The invention relates to a novel method for selecting an immunosuppressive agent with a less thrombocytopenia effect. According to the invention, a method for selecting an immunosuppressive agent which has a potent immunosuppressive activity but a lower thrombocytopenia effect, said method comprising measuring an IL-2 transcription inhibitory activity in a ... 06/15/06 - 20060128605 - Preventives/remedies for snore or respiratory disturbances during sleep Compounds which have an agonist action on a glycine receptor and compounds capable of being present as glycine in living organisms are effective for the prophylaxis or treatment of snoring or respiratory disorders during sleep. Foods and diets which contain such a compound are also effective for the prophylaxis or ... 06/08/06 - 20060122096 - Reversible modification of amine-containing compounds An process for the reversible modification of an amine-containing compound is described. Modification of the compound can be used to facilitate delivery of molecules to cells in vitro and in vivo or to alter interactions or activities the compounds. The described modifiers can also be utilized as cross-linkers. ... 06/08/06 - 20060122095 - Mucus formulation for mucosal surfaces and uses thereof The present invention includes formulations comprising synthetic vaginal fluid, synthetic cervical mucus, and, a mixture of a synthetic cervical mucus and synthetic vaginal fluid suitable for mucosal administration of at least one therapeutic agent. The formulations of the invention are useful in the treatment, prevention and control of diseases and ... 06/01/06 - 20060116315 - Method of screening agent for improving memory and learning ability A screening tool and a screening method of a substance which is useful as an agent for improving the memory, an agent for improving learning ability, and/or an antidementia agent; a polypeptide, a polynucleotide, a vector, and a cell which may be used in the above screening; and a novel ... 05/25/06 - 20060111274 - Methods and compositions for enhancing transport across biological membranes Methods and compositions for transporting drugs and macromolecules across biological membranes are disclosed. In one embodiment, the invention pertains to a method for enhancing transport of a selected compound across a biological membrane, wherein a biological membrane is contacted with a conjugate containing a biologically active agent that is covalently ... 05/25/06 - 20060111273 - Water soluble paclitaxel derivatives Disclosed are water soluble compositions of paclitaxel and docetaxel formed by conjugating the paclitaxel or docetaxel to a water soluble polymer such as polyglutamic acid, poly-aspartic acid or poly-lysine. Also disclosed are methods of using the compositions for treatment of tumors, auto-immune disorders such as rheumatoid arthritis. Other embodiments include ... 05/25/06 - 20060111272 - Metabolically inert antifolates for treating disorders of abnormal cellular proliferation and inflammation The present invention provides compositions and methods for the treatment of disorders of abnormal cell proliferation and/or inflammation, such as psoriasis and inflammatory bowel disease, in a human or other host animals. ... 05/25/06 - 20060111271 - Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements The present invention relates to vaccine conjugates composed of a hapten linked to a carrier compound, which are used for active or passive immunization in order to elicit antibodies against the hapten. The carrier compound used in the present invention is composed of a multitude of typically dozens of similar ... 05/18/06 - 20060105939 - Treatment of autism and similar disorders Methods of treating certain behavioral characteristics associated with autism are provided. Additionally, methods of treating disorders associated with repetitive behaviors, social deficits and/or cognitive deficits are also provided. A therapeutic amount of oxytocin or oxytocin analogs, either alone or in combination, are administered to individuals demonstrating behavioral characteristics associated with ... 05/18/06 - 20060105938 - Method of treating or preventing obeisity and lipid metabolism disorders and compositions for use therein The present invention provides a method of preventing or treating human obesity, said method comprising ingesting a composition containing, calculated on dry matter: 10-100 wt. % protein hydrolysate; 0-90 wt. % intact protein; 0-50 wt. % carbohydrate; and wherein hydrolysed protein and intact protein together are present in a concentration ... 05/11/06 - 20060100136 - Synergistic effects of combined administration of mirtazapine and a stimulant compound The invention discloses combination therapies and formulations of a stimulant (e.g., amphetamine) and mirtazapine and their methods of use. ... 05/11/06 - 20060100135 - Compositions and methods for modifying toxic effects of proteinaceous compounds The present invention provides methods to produce immunotoxins (ITs) and cytokines with a reduced ability to promote vascular leak syndrome (VLS). The invention also provides ITs and cytokines which have been mutated to lack amino acid sequences which induce VLS. ... 05/11/06 - 20060100134 - Membrane penetrating peptides and uses thereof The present invention is directed to membrane penetrating peptides useful as in viv, ex vivo and in vitro intracellular delivery devices for compound of interest. More particularly, the invention involves identification of membrane penetrating peptides which may be used as protein carriers for delivery of a compound of interest to ... 05/11/06 - 20060100133 - High beta-conglycinin products and their use The utility of soybeans having a composition of greater than 40% of the protein as beta-conglycinin and less than 10% of the protein as glycinin for making highly functional high beta-conglycinin compositions was discovered. The discovered ingredients are useful for mimicking the texturizing properties of casein while also maintaining or ... 05/11/06 - 20060100132 - Method for diagnosing inflammatory bowel disease The present invention relates to a method for identifying a compound capable of modulating the action of the DLG5 protein which method comprises subjecting one or more test compounds to a screen comprising a polypeptide containing the amino acid sequence shown in SEQ ID NO: 2, or a homologue thereof ... 05/11/06 - 20060100131 - Modulation of stem cell differentiation by modulation of caspase-3 activity Methods of directing stem cell fate for therapeutic purposes through the deliberate manipulation of caspase-3 activity are provided. The use of modulators of caspase-3 activity to modulate stem cell differentiation is described including activators and/or effectors of caspase-3, which can be used to induce stem cell differentiation, and inhibitors of ... 05/11/06 - 20060100130 - Catalysis of the cis/trans-isomerisation of secondary amide peptide compounds The present invention is based on the finding that the cis/trans isomerisation of secondary amide peptide bonds in oligo- and polypeptides can be catalytically promoted. This catalysis is effected by enzymes which are hereinafter called “secondary amide peptide bond cis/trans isomerases (APIases). It can be assumed that the APIase activity ... 05/04/06 - 20060094642 - Method of increasing bone toughness and stiffness and reducing fractures The invention relates to a method for increasing the toughness and/or stiffness of bone and/or reducing the likelihood and/or severity of bone fracture by administering a parathyroid hormone. The method can be employed to increase toughness or stiffness of bone at a site of a potential or actual trauma, such ... 05/04/06 - 20060094641 - Method for providing natural therapeutic agents with high therapeutic index Methods for identifying and providing new therapeutic agent(s) by selecting at least one polypeptide encoded by a natural allelic variant of one preselected gene having a therapeutic potential; determining the therapeutic index of the selected polypeptide(s) and retaining as therapeutic agent(s) those polypeptide(s) whose therapeutic index is higher than that ... 04/27/06 - 20060089297 - Sperm specific lysozyme-like proteins The present invention is directed to a family of testis specific proteins (SLLPs) that share high sequence identity to lysozyme-C proteins. The application encompasses compositions comprising the SLLP proteins, antibodies specific for the SLLP polypeptides and the use of the SLLP polypeptides and antibodies directed to such peptides as contraceptive ... 04/20/06 - 20060084592 - Peptide boronic acid inhibitors where the ring portion of any of said aryl, aralkyl, alkaryl, cycloalkyl, heterocyclyl, or heteroaryl in R1, R2, R3 or R5 can be optionally substituted. ... 04/20/06 - 20060084591 - Use of modulators of the signal transduction path using the protein kinase fyn for the treatment of tumorous diseases The present invention describes the use of modulators of the signal transduction pathway via the protein kinase Fyn (e.g. Rho-kinase inhibitors or inhibitors of the protein kinase CSK) in the treatment of tumour diseases, especially in the therapy of neuroblastoma. ... 04/13/06 - 20060079449 - Inhibition of smad3 to prevent fibrosis and improve wound healing The invention is related to modulation of Smad3 expression to prevent fibrosis and improve wound healing. Aspects of the invention, for example, include approaches to improve wound healing and/or reduce or prevent fibrosis by inhibiting Smad3. Embodiments described herein also include approaches to identify componds that modulate Smad3 expression and ... 04/13/06 - 20060079448 - Compounds and methods for increasing neurogenesis The invention is directed to methods of promoting neurogenesis by contacting neuronal tissue with neurogenesis modulating agents. Novel methods for treating neurological disorders using neurogenesis modulating agents are disclosed. ... 04/13/06 - 20060079447 - Stabilized a-beta protofibrillar aggregates Described and claimed herein are methods for producing chemically stabilized Aβ protofibrillar aggregates, and compositions made therefrom. Compositions produced are useful in facilitating detailed studies of Aβ protofibril structure, fibril formation, and progression of Aβ related diseases, e.g., Alzheimers disease. In addition, chemically stabilized protofibrillar structures can be used as ... 04/13/06 - 20060079446 - Methods and compositions for treating hypercholesterolemia The present invention provides methods and compositions for treating hypercholesterolemia using therapeutic apoE proteins. A therapeutic apoE protein is a naturally-occurring apoE protein (e.g., apoE1, apoE2, apoE2*, apoE2**, apoE3, and apoE4) that has one or more amino acid substitutions in the carboxy-terminal region which, when administered to a mammal having ... 04/13/06 - 20060079445 - Camkii/calcium channel binding-related compositions and methods This invention provides a method for determining whether an agent inhibits binding between CaMKII and a Ca+2 channel. Furthermore, this invention provides a method for inhibiting binding between CaMKII and a Ca+2 channel in a cell. Finally, this invention provides methods of treating cardiac arrhythmia and neurological disorders. ... 04/13/06 - 20060079444 - Human sef isoforms and methods of using same for cancer gene therapy A method and pharmaceutical compositions useful for inhibiting the growth of solid tumors are provided. Specifically, the method is effected by administering to a subject in need thereof an agent capable of upregulating the expression level and/or activity of at least a functional portion of Sef, wherein the functional portion ... 04/13/06 - 20060079443 - Methods and uses of leptin in immune modulation The present invention describes the use of leptin for the immune modulation of the Th1/Th2 response. One aspect of the invention provides for a shift in the Th1/Th2 cell balance towards pro-inflammatory cytokine producing cells. This shift results from an increase in the levels, expression and/or the activity of leptin. ... 04/13/06 - 20060079442 - Methods and uses of leptin in immune modulation and hepatocellular carcinoma Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed ... 04/13/06 - 20060079441 - Methods of modulating angiogenesis The present invention relates to methods for modulating angiogenesis. In some embodiments the methods include a step of contacting a cell experiencing or susceptible to angiogenesis with a composition comprising a multi-unit complex that comprises a tRNA synthetase fragment. The multi-unit complex can include two or more monomer units. Two ... 04/13/06 - 20060079440 - Treatment of hi-virus infections with oxidised blood proteins The invention relates to the field of medicaments for combating an infection of a host cell by HI viruses and/or for inhibiting binding of an Env protein to a CD4 protein. For these purposes, the invention provides medicaments which comprise oxidized proteins, oxidized peptides and/or peptidomimetics of such oxidized proteins ... 04/13/06 - 20060079439 - Elastin prevents occlusion of body vessels by vascular smooth muscle cells The present invention provides methods and compositions for promoting elastin signaling in smooth muscle cells including vascular smooth muscle cell. The present invention further provides methods of identifying additional agents that promote elasfin signaling. ... 04/06/06 - 20060074012 - Treatment of gestational diabetes Methods for treating gestational diabetes which comprise administration of an effective amount of an exendin or an exendin agonist, alone or in conjunction with other compounds or compositions that lower blood glucose levels. ... 04/06/06 - 20060074011 - Compositions providing for increased igf-i solubility Novel IGF-I compositions are described. The compositions include a solubilizing compound comprising a guanidinium group that provides for IGF-I compositions in which IGF-I is highly soluble at pHs of about 5.5 or greater and at refrigerated temperatures. ... 04/06/06 - 20060074010 - Method and apparatus for purifying pharmaceutical compositions using supercritical fluids The present invention provides a method and an apparatus for removing impurities from biodegradable polymers and/or pharmaceutical compounds. In accordance with the method, a stream of supercritical fluid and, optionally, a modifying co-solvent, is used to dissolve the impurities. The pressure and temperature of the supercritical fluid or supercritical fluid/co-solvent ... 04/06/06 - 20060074009 - Natriuretic compounds, conjugates, and uses thereof Modified natriuretic compounds and conjugates thereof are disclosed in the present invention. In particular, conjugated forms of hBNP are provided that include at least one modifying moiety attached thereto. The modified natriuretic compound conjugates retain activity for stimulating cGMP production, binding to NPR-A receptor, and in some embodiments an improved ... 04/06/06 - 20060074008 - Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease Drug-Linker-Ligand Conjugates are disclosed in which a Drug is linked to a Ligand via a peptide-based Linker unit. In one embodiment, the Ligand is an Antibody. Drug-Linker compounds and Drug compounds are also disclosed. Methods for treating cancer, an autoimmune disease or an infectious disease using the compounds and compositions ... 04/06/06 - 20060074007 - Unique dendritic cell-associated c-type lectins, dectin-1 and dectin-2; compositions and uses thereof Novel genes expressed selectively by long-term dendritic cell (DC) lines (XS series) from murine epidermis which retain important features of resident epidermal Langerhans cells (LC) are provided. These genes encode distinct type II membrane-integrated polypeptides, each consisting of a cytoplasmic domain, a transmembrane domain, an extracellular connecting domain, and a ... 03/30/06 - 20060069012 - Methods and compositions for treating plasticity in a subject Methods and compositions for at least maintaining plasticity in a system of a subject are provided. Embodiments of the subject methods include lowering long term potentiation in said subject in a manner effective to at least maintain plasticity of a system in said subject. ... 03/30/06 - 20060069011 - Method for treatment and repair of meniscal injuries A method for repair of meniscal injuries comprising induction of meniscal regeneration by introducing a strongly adhesive collagen-polyethylene glycol (PEG) hydrogel to a site of injury. ... 03/30/06 - 20060069010 - Detoxification depot for alzheimer's disease The invention is directed to a device that is placed inside an Alzheimer's disease (AD) patient for the purpose of extracting and accumulating neurotoxic beta-amyloid peptides (nt-bAP) from body fluids. AD is the consequence of a process in which nt-bAP aggregates to form fibrils and plaques which can cause nerve ... 03/30/06 - 20060069009 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering BMP7 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations having the ... 03/30/06 - 20060069008 - Treatment of neurological deficits in the striatum or substanta nigra pars compacta The present invention is directed to methods of treating neurological deficits resulting from injury or disease to the striatum or substanta nigra pars compacta of a human by administering human recombinant GDF5 to the striatum or substanta nigra pars compacta of a human in amounts effective to induce cell populations ... 03/23/06 - 20060063705 - Use of alpha-msh and epo for preventing or treating ischemic conditions Alpha-melanocyte stimulating hormone (α-MSH) or an equivalent is used, in conjunction with erythropoietin (EPO) or equivalent, to prevent or treat ischemic conditions. ... 03/23/06 - 20060063704 - Somatostatin-dopamine chimeric analogs The invention features somatostatin-dopamine chimeric analogs and methods relating to their therapeutic use for the treatment of neoplasia, acromegaly, and other conditions. ... 03/23/06 - 20060063703 - Methods for treating cancer-related fatigue Methods for treating cancer patients suffering from severe and persistent fatigue, diagnosed as Cancer-Related Fatigue (CRF), with thyrotropin-releasing hormone (TRH) and peptidomimetic analogs of TRH. ... 03/23/06 - 20060063702 - Neuromedin u 2 receptor agonists and uses thereof This invention provides neuromedin U 2 receptor (NMU-2R) agonists. This invention further provides a method for screening and identification of said agonist. This invention also provides the core structure for NMU-2R agonists. This invention provides that the agonist can effectively reduced body weight of high fat diet induced obese rats ... 03/23/06 - 20060063701 - Methods and compositions for modulating c5-a-mediated inflammatory responses PL37 (RAARISLGPRICKAFTE [SEQ ID NO: 2]) is an Antisense Homolgoy Box peptide composed of amino acids 37 to 53 of C5a-anaphylatoxin. Complementary peptides, ASGAPAPGPAGPLRPMF (Pep-A [SEQ ID NO: 1]) and ASTAPARAGLPRLPKFF (Pep-B [SEQ ID NO: 3]) were designed and characterized. Pep-A bound to PL37 and to C5a with very slow ... 03/23/06 - 20060063700 - Methods to stimulate insulin production by pancreatic beta-cells The invention features a method of treating deficiency of insulin in a patient, comprising administering to a patient in need thereof hedgehog protein or nucleic acid in an amount effective to raise the level of insulin in the patient. ... 03/23/06 - 20060063699 - Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising petide sequence (Z) of 4-20 amino acid residues covalently bound to X. ... 03/23/06 - 20060063698 - Medicament composition and method of administration A medicament powder, system and method for nasal administration of a pharmacologically active peptide across the nasal mucous membrane. A free-flowing powder having a low moisture content includes a cross-linked cation exchange resin in anionic form and a pharmacologically active peptide in cationic form ionically bound together. The particles of ... 03/16/06 - 20060058224 - Methods of treating obesity with combination therapeutics Compositions and methods of treating obesity or obesity-related condition, including reducing body-weight, improving-diabetic parameters, metabolic syndrome. liver steatosis, and/or hypertension with a combination of CNTF or a CNTF-related molecule and a second agent which is a therapeutic molecule useful in the treatment of obesity, type II diabetes, or other obesity-related ... 03/16/06 - 20060058223 - Taj in neuronal function The invention provides methods of treating diseases, disorders, injuries, or conditions involving modulating neurite outgrowth and/or survival, including CNS disorders, stroke, or spinal injury, by administration of a TAJ antagonist. ... 03/16/06 - 20060058222 - Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders A compound provided by the present invention includes an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently bonded to a biologically active peptide. One example of an inventive compound described is a conjugate of an endocannabinoid, endocannabinoid derivative, or endocannabinoid analog moiety covalently coupled to an opioid peptide, such as ... 03/16/06 - 20060058221 - Baclofen conjugate and a pharmaceutical composition for treatment of neuronal disorders where R1 is p-chlorophenyl, R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, ... 03/16/06 - 20060058220 - Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same Hapten-carrier conjugates capable of eliciting anti-hapten antibodies in vivo by administering, in a therapeutic composition, are, disclosed. Methods of preparing said conjugates and therapeutic compositions are also disclosed. Where the hapten is a drug of abuse, a therapeutic composition containing the hapten-carrier conjugate is particularly useful in the treatment of ... 03/16/06 - 20060058219 - Aminobutyramide conjugate and a pharmaceutical composition for treatment of neuronal disorders where R is a moiety capable of crossing the blood brain barrier and is as a free compound serotonin, dopamine blood brain barrier (BBB) peptide, membrane translocating protein, TAT peptides, bradykinin, beta-endorphin, bombesin, calcitonin, cholecystokinin, an enkephalin, dynorphin, insulin, gastrin, substance P, neurotensin, glucagon, secretin, somatostatin, motilin, vasopressin, oxytocin, prolactin, ... 03/16/06 - 20060058218 - Solid phase conjugation of complexing agents and targeting moieties There is provided a technique for conjugating one or more complexing agents with a targeting moiety, such as natural amino acids, unnatural amino acids, peptides, peptide nucleic acids, nucleotides, and analogs and derivatives thereof. The one or more complexing agents are conjugated at one or more free amino groups of ... 03/16/06 - 20060058217 - Compositions and methods for treatment of ovarian cancer Compositions and methods for treatment of ovarian cancer are described. The compositions comprise antalamin, a compound that increases cytotoxic T-cell lytic activity at tumor sites. Methods of treatment for ovarian cancer are based on the administration of antalarmin to increase cytotoxic T-cell lytic activity or anti-tumor activity, which leads to ... 03/09/06 - 20060052285 - Mechanism of mitochondrial membrane permeabilization by hiv-1 vpr, mimetics of vpr and methods of screening active molecules having the ability to alter and/or prevent and/or mimic the interaction of vpr with ant The invention is directed to the induction of mitochondrial membrane permeabilization via the physical and functional interaction of the HIV-1 Vpr protein with the mitochondrial inner membrane protein ANT (adenine nucleotide translocator, also called adenine nucleotide translocase or ADP/ATP carrier). Reagents and methods for inducing and/or inhibiting the binding of ... 03/09/06 - 20060052284 - Novel peptide conjugates including methods of making and using such conjugates. Also provided are antibodies that specifically bind the peptide conjugates. The present invention has a wide spectrum of important applications including use in the treatment of disorders impacted by nociceptin and related opioid-like peptides. ... 03/09/06 - 20060052283 - The sperm binding ligand hiprty and its involvement in embryo cleavage A sperm-binding ligand sequence with the amino acid sequence HIPRTY is claimed. Using proprietary bio-informatic analysis, this sperm-binding ligand sequence was shown to also precisely correspond with a previously characterized highly conserved protein-protein interaction site in the Axin protein at position 370 to 375. The Axin protein sequence HIPRTY is ... 03/09/06 - 20060052282 - Diagnostic and therapeutic means for pathologies associated with alpha 2 subunit of the na, k pump A nucleic acid is described that comprises at least one segment of the gene encoding a functional segment of the alpha 2 subunit of the Na,K pump (ATPase, ATP1A2) for use in the diagnosis or treatment of pathologies associated with migraine or with alternating hemiplegia of the childhood. Appropriate diagnostic ... 03/09/06 - 20060052281 - Protein s protects the nervous system from injury Protein S is a significant neuroprotectant when administered after focal ischemic stroke and prevents hypoxic/re-oxygenation injury. Purified human plasma-derived or recombinant protein S improves motor neurological function after stroke, and reduced brain infarction and edema. Protein S also enhances post-ischemic reperfusion and reduced brain fibrin and neutrophil deposition. Cortical neurons ... 03/09/06 - 20060052280 - Diagnostic and therapeutic use of a golgi protein for neurodegenerative diseases The present invention discloses the differential expression of golgin-245 in specific brain regions of Alzheimer's disease patients. Based on this finding, this invention provides a method for diagnosing or prognosticating a neurodegenerative disease, in particular Alzheimer's disease, in a subject, or for determining whether a subject is at increased risk ... 03/02/06 - 20060046956 - Acylsulfonamide compounds as inhibitors of hepatitis c virus ns3 serine protease The present invention discloses novel compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such compounds as well as methods of using them to treat disorders associated with the HCV protease. ... 02/23/06 - 20060040853 - Methods and compositions useful for modulation of angiogenesis using protein kinase raf and ras The present invention describes methods for modulating angiogenesis in tissues using Raf and/or Ras protein, modified Raf or Ras protein, and nucleic acids encoding for such. Particularly the invention describes methods for inhibiting angiogenesis using an inactive Raf and/or Ras protein, or nucleic acids encoding therefor, or for potentiating angiogenesis ... 02/23/06 - 20060040852 - Il-1 antagonist formulations Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion protein having an amino acid sequence selected from the group consisting of SEQ ID ... 02/23/06 - 20060040851 - Topical compositions for the treatment, protection and restoration of skin and connective tissues The invention relates to uses of GAG-peptide complexes and polypeptides obtained from connective tissue albeit indirectly which are substantially free of DNA for the treatment, protection and restoration of skin and connective tissues. The invention provides a topical composition comprising at least on GAG-peptide complex comprising two or three GAG-chains. ... 02/23/06 - 20060040850 - Use of enzyme inhibitors with aminopeptidase n and/or dipeptidylpeptidase iv activities and pharmaceutical preparations produced therefrom for the therapy and prevention of dermatological diseases with seborrhoeic hyperproliferation and altered differenti The invention relates to a process for the-inhibition of the DNA synthesis necessary for the proliferation of human sebaceous cells (sebocytes) by the isolated or joint effect of inhibitors of alanyl aminopeptidase (APN) and dipetidyl peptidase IV (DP IV) expressed by these cells. The DNA synthesis (proliferation) of human sebaceous ... 02/16/06 - 20060035812 - Neuroprotective dietary supplement The invention relates to a novel dietary supplement mixture having improved neuroprotective activity and preventing, ameliorating or counteracting neurodegeneration and preventing, counteracting and/or improving cognitive function decline. It also provides a dietary supplement, which is to be administered in an oral dosage form. ... 02/16/06 - 20060035811 - Methods of treating dry eye disease with lantibiotics The treatment of dry eye disease with lantibiotics such as duramycin is described, along with pharmaceutical formulations useful for carrying out such treatments. ... 02/09/06 - 20060030517 - Anti-cancer agent The invention relates to an anti-cancer agent containing α-chain protein (α-fragment) of HGF (hepatocyte growth factor) as an active ingredient. The active ingredient of α-fragment has a specific suppressing effect on invasion and metastasis of cancer cells such as gallbladder cancer, lung cancer and other, which are highly metastatic and ... 02/02/06 - 20060025331 - Vascular endothelial growth factor 2 Disclosed are human VEGF2 polypeptides, biologically active, diagnostically or therapeutically useful fragments, analogs, or derivatives thereof, and DNA (RNA) encoding such VEGF2 polypeptides. Also provided are procedures for producing such polypeptides by recombinant techniques and antibodies and antagonists against such polypeptides. Such polypeptides may be used therapeutically for stimulating wound ... 02/02/06 - 20060025330 - Electrostatic bonding type macromolecular micelle drug carrier and drug carried thereon The present invention provides an electrostatic bonding macromolecular micelle drug carrier comprising a block copolymer having a non-chargeable segment and a chargeable segment, for stably carrying a chargeable drug tending to be easily decomposed in vivo such as protein and DNA. ... 02/02/06 - 20060025329 - Compositions and methods for inhibiting cellular proliferation comprising tfpi fragments Compositions and methods effective in inhibiting abnormal or undesirable cell proliferation, particularly endothelial cell proliferation and angiogenesis related to neovascularization and tumor growth are provided. The compositions comprise a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of the C-terminal portion of proteinase ... 02/02/06 - 20060025328 - Compositions suitable for controlled release of the hormone gnrh and its analogs A liquid composition for the controlled release of gonodotropin releasing hormone (GnRH) or its analogs or agonists is provided that includes: (i) a non-polymeric, non-water soluble liquid carrier material (HVLCM) of viscosity of at least 5,000 cP at 37° C. that does not crystallize neat under ambient or physiological conditions; ... 02/02/06 - 20060025327 - Hybrid molecules qa, wherein q is an aminoquinoline and a is an antibiotic or a resistance enzyme inhibitor, their synthesis and their uses as antibacterial agent Q represents an aminoquinoline, (Y1)p—(U)p′—(Y2)p″— is an optional spacer arm and A is an antibiotic, one of its derivatives or precursors, or a resistance enzyme inhibitor. The invention unexpectedly enables the activity of the antibiotic to be improved. ... 02/02/06 - 20060025326 - Method for treating carrier particles and its use A method for treating a particulate carrier for an inhalation powder improving the stability and flowing properties of the carrier. The carrier is abraded suspended in a liquid medium, in which the carrier is essentially insoluble, the liquid medium is evaporated and the carrier recovered. ... 01/26/06 - 20060019871 - Endothelial cell apoptosis induced by fibrinogen gamma chain c-terminal fragment The present invention provides for the novel use of a polypeptide related to a fibrinogen γ chain C-terminal fragment or a nucleic acid encoding the polypeptide for inhibiting endothelial cell proliferation. Methods of using the polypeptide or the nucleic acid are provided. Also provided are compositions containing the polypeptide or ... 01/26/06 - 20060019870 - Apoprotein cochleate compositions Disclosed herein are cochleates and cochleate compositions associated with an apoprotein component and/or a plasmid component that encodes an apoprotein. Also disclosed are methods of making and using the compositions of the invention, including methods of administration. Use of the invention provides safe, effective and efficient delivery of apoproteins and/or ... 01/26/06 - 20060019869 - Intradiscal anti-inflammatory therapy involving autologous adiponectin Administering an effective amount of APN into an intervertebral disc is disclosed. ... 01/26/06 - 20060019868 - Hemostatic compositions and devices The present invention includes both sterilized and unsterilized hemostatic compositions that contain a continuous, biocompatible liquid phase having a solid phase of particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid phase, and a discontinuous, biocompatible gaseous phase, each of which ... 01/19/06 - 20060014669 - Method for treating cancer and increasing hematocrit levels The present invention provides a method for inhibiting undesired angiogenesis including tumor-associated angiogenesis. The invention further provides a method for increasing the number of red blood cells or hematocrit in the circulation in subjects in need thereof. The invention also provides a method for simultaneously treating low hematocrit and undesired ... 01/19/06 - 20060014668 - Antigenic gp 100 compounds for therapy and diagnosis and methods of using same The present invention provides methods and compositions for detecting, diagnosing, prognosing and monitoring the progress of gp 100-related cancers and malignancies and kits for use in said methods. Further provided are methods for screening to identify agonists and antagonists of cancer antigens associated with gp 100 related cancers and malignancies. ... 01/19/06 - 20060014667 - Peptide composition and method for delivering substances into the cytosol of cells Weak-base amphiphilic delivery peptide compositions are described for use in delivering large polar substances (cargo) into the cytosol of animal cells via an indirect endocytosis-mediated delivery process. The delivery peptides, which are predominantly non-ionic at neutral pH, bind but do not permeabilize cell membranes. After endocytosis of both delivery peptides ... 01/19/06 - 20060014666 - Targeted hydrophilic polymer, binders with interferon and medical composite comprising above binders The present invention relates to an active targeted water-solubility macromolecule polymer, conjugate With interferon and pharmaceutical composition comprising the conjugate. The targeted agent includes, for example, glucose, galatose and the like, as well as their derivates. The conjugate of the present invention is well in water-solubility and havc long physiological ... 01/19/06 - 20060014665 - Therapeutic agent The invention relates to an agent for the depletion of unwanted proteins from plasma comprising a plurality of ligands covalently co-linked to produce a complex with a plurality of proteins wherein at least two of the ligands are capable of being bound by ligand binding sites on the proteins and ... 01/12/06 - 20060009377 - Long lasting synthetic glucagon like peptide (glp-1) Modified insulinotropic peptides are disclosed. The modified insulinotropic peptides are capable of forming a peptidase stabilized insulinotropic peptide. The modified insulinotropic peptides are capable of forming covalent bonds with one or more blood components to form a conjugate. The conjugates may be formed in vivo or ex vivo. The modified ... 01/12/06 - 20060009376 - Stable therapeutic proteins The invention relates to storable medicaments produced from pharmaceutical active ingredient preparations which are virus safe. Said medicaments contain at least one intact therapeutic protein obtained from plasma or by means of genetic engineering, as an active pharmaceutical substance. Said active ingredient preparations contain active enzymes, especially proteases, which are ... 01/12/06 - 20060009375 - Site-specific drug delivery Compounds and methods which are useful for the site-specific delivery and localization of drugs are provided. The compounds can be represented by the formula: A-L-D wherein A is an anchoring moiety; L is a linking group; and D is a drug. ... 01/12/06 - 20060009374 - Antibacterial peptide The present invention provides a novel peptide based on CAP11 as well as provides an antibacterial agent, an LPS-cell-binding inhibitor, and a drug such as a bacterial-infection-treating agent or an endotoxin-shock suppressant, each containing the peptide as an active ingredient. The peptide has the following amino acid sequence (SEQ ID ... 01/12/06 - 20060009373 - Method for treating diabetic wounds A method for treating diabetic wounds uses a topical preparation containing insulin in combination with glucose. The exact proportions are not critical, as the presence of even a trace amount of either component in combination with the other is effective. In one embodiment, the composition contains from about 0.1% to ... 01/05/06 - 20060003921 - Pharmaceutical preparation comprising vwf propeptide Described is a pharmaceutical preparation for treating blood coagulation disorders comprising an effective amount of vWF propeptide as well as a method for producing such a preparation. ... 01/05/06 - 20060003920 - Lat1 transporters expressed in cancer cells LAT1 is consistently expressed at high levels in cancer cells. Disclosed herein are assays for determining whether a test material/molecule is a substrate for, and/or is transported by, the LAT1 transporter, and therefore a candidate substrate for transport into cancer cells. The assays are useful in screening for cytotoxic agents ... 01/05/06 - 20060003919 - Cosmetic/dermatological applications of lif Leukemia inhibitory factor (“LIF”), an LIF analogue, an LIF mimetic, a product capable of stimulating the expression of endogenous LIF and mixtures thereof are useful for maintaining and/or stimulating the regenerative power of a population of human undifferentiated skin stem cells and/or epidermal progenitors, and are also useful for treating ... 01/05/06 - 20060003918 - Prolonged delivery of peptides There are disclosed methods for the treatment of non-insulin dependent diabetes mellitus in a mammal comprising the prolonged administration of GLP-1 (7-37), and related peptides. Also disclosed are compositions to prolong the administration of the peptides. ... 01/05/06 - 20060003917 - Bisphosphonate coated implant device and method therefor The method of the present invention is for coating an implant device. The implant device is coated with a protein film, such as fibrinogen. A first bisphosphonate substance, such as pamidronate, is immobilized to the protein film. A second bisphosphonate substance, such ibandronate, is adsorbed to the first bisphosphonate wherein ... 01/05/06 - 20060003916 - Use of pthrp antagonists for treating renal cell carcinoma The present invention concerns the use of a PTHrP antagonist for preparing a pharmaceutical composition for treating renal cell carcinoma (RCC) in a mammal and in particular in a human subject. Advantageously, the invention is of particular interest for inhibiting or reducing tumour growth and/or metastasis formation in kidney cancer ... 01/05/06 - 20060003915 - Means and methods for the specific modulation of target genes in the cns and the eye and methods for their identification Provided are methods for the treatment of disorders of the central nervous system (CNS) and the eye. In particular, use of compositions comprising a compound capable of modulating a target gene or gene product is described for the preparation of a pharmaceutical composition for the treatment of disorders of the ... 12/29/05 - 20050288215 - Inhibition of nuclear export as a treatment for cardiac hypertrophy and heart failure The present invention provides methods of treating cardiac hypertrophy by administering a drug that is known to be a non-selective inhibitor of nuclear protein export to patient in need thereof. ... 12/29/05 - 20050288214 - Nucleotide sequence encoding ptd and cea fusion protein, tat-cea fusion protein, anti-tumor vaccine and pharmaceutical composition for treating tumor comprising the fusion protein A nucleotide sequence encoding a fusion protein of PTD and CEA. The nucleotide sequence includes a CEA-encoding nucleotide sequence into which a PTD-encoding nucleotide sequence is inserted. ... 12/29/05 - 20050288213 - Combination therapy for the treatment of obesity and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides ... 12/29/05 - 20050288212 - Components of the presenilin-complex The present invention is based on a novel direct interaction between a Presenilin and a novel protein identified herein and named Sambiasin-1, a homolog thereof named Sambiasin-2, as well as a protein complex further comprising a Nicastrin. Also comprised are uses of said components and complexes, as well as methods ... 12/29/05 - 20050288211 - Chemotactic factor inhibitor for modulating inflammatory reactions The present invention relates to compounds and methods for modulating, reducing or inhibiting, inflammatory reactions in a patient. Particularly, inflammatory reactions that are targeted by the present invention are cell migration, secretion of toxic products and proteolysis at a site of inflammation. Reduction of inflammation manifestations and reactions occurs by ... 12/22/05 - 20050282737 - Procollagen (iii) propeptides and related substances for treating fibrotic diseases In a method of treating a fibrotic disease, a composition is administered to a mammal an effective amount, wherein the composition contains a polypeptide selected from the group consisting of rat, mouse, and human N-terminal procollagen (III) propeptide and rat, mouse, and human C-terminal procollagen (III) propeptide and further contains ... 12/22/05 - 20050282736 - Methods for cyclizing synthetic polymers The invention provides methods and compositions for production of a cyclic polymer in a cell free system. In general, the methods of the invention involve ligating first and second recombinant intein domains to a linear synthetic polymer to form a compound containing the structure: D1-X(n)-D2, where D1 is a first ... 12/22/05 - 20050282735 - Use of plasma proteins concentrates containing vwf with a high proportion of high molecular weight multimers Use of plasma proteins concentrates containing VWF with a high proportion of high molecular weight multimers prevents a bleeding diathesis and reduces pre-, peri- and postoperative blood loss in acquired Von Willebrand syndromes such as in cardiovascular diseases requiring surgical procedures, especially those requiring extracorporeal circulation. ... 12/22/05 - 20050282734 - Pharmaceutically acceptable composition comprising an aqueous solution of paclitaxel and albumin An optically clear, pharmaceutically acceptable aqueous composition comprising paclitaxel or a derivative thereof, serum albumin and a pharmaceutically acceptable vehicle, wherein the composition comprises no more than 10% organic solvent and has a pH of about 3.0 to about 4.8, is described. The serum albumin can be fatted or defatted, ... 12/22/05 - 20050282733 - Differentiation modulating agents and uses therefor The present invention is directed to methods and agents for modulating the differentiation potential and/or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, ... 12/22/05 - 20050282732 - Pharmaceutical compositions and treatment methods-7 The invention provides compositions comprising formula 1 steroids, e.g., 16α-bromo-3β-hydroxy-5α-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. The compositions are useful to make improved pharmaceutical formulations. The invention also provides methods of intermittent dosing of steroid compounds such as analogs of ... 12/22/05 - 20050282731 - Administration form for pharmaceutically active peptides with sustained release and method for the production thereof The invention relates to pharmaceutical administration forms with sustained release comprising at least one pharmacologically active peptide. The invention also relates to a method for the production thereof, a kit comprising a lyophilised peptide and an aqueous solution of an inorganic salt or acetic acid salt and the use of ... 12/22/05 - 20050282730 - Thrombopoetin receptor activator and process for producing the same [wherein each of R1 and R3 is independently a hydrogen atom, SO3H, a C1-6 alkyl group, a C1-6 alkylcarbonyl group or a C6-18 arylcarbonyl group (the C1-6 alkyl group, the C1-6 alkylcarbonyl group and the C6-18 arylcarbonyl group may be optionally substituted with a halogen atom, a hydroxyl group, a ... 12/22/05 - 20050282729 - Crisp polypeptides as contraceptives and inhibitors of sperm capacitation Included in the present invention are methods of inhibiting sperm capacitation, inhibiting the phosphorylation of a protein at tyrosine residues, inhibiting an acrosomal reaction, and inhibiting fertilization of an egg by sperm with the administration of a CRISP polypeptide. ... 12/15/05 - 20050277578 - Immunity generation A method for the manufacture of a medicament for immunity generation includes the use of insect tissues, larval forms or derivatives of insects that have been fed on a food containing pathogens. ... 12/15/05 - 20050277577 - Compositions and methods for treating diverticular disease Agents, compositions, and implants are provided herein for treating diverticular disease (e.g., diverticulosis and diverticulitis). In particular, fibrosis-inducing agents, hemostatic agents, and/or anti-infective agents, or compositions containing one or more of these agents are provided for use in methods for treating diverticular disease. ... 12/15/05 - 20050277576 - Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs Acute and chronic diseases of the organs are treated using a rational, multi-tier approach. A patient is pretreated with growth factor proteins or gene therapy, followed by the administration of adult stem cells. The patient can be a fetus treated in utero or removed from the womb. The progress of ... 12/15/05 - 20050277575 - Therapeutic compositions and methods for treating diseases that involve angiogenesis According to the present invention, S100A4 protein also known as Mts-1 interferes with the function of Annexin 2 and Annexin2/P11 tetramer by binding to Annexin 2. The present inventors have demonstrated that binding of S100A4 with Annaxin 2 modulates angiogenesis by interfering with Annexin 2 mediated tissue plasminogen activator (tPA) ... 12/08/05 - 20050272638 - Compounds and compositions for delivering active agents Compounds and compositions for the delivery of active agents are provided. Methods of administration and preparation are provided as well. ... 12/08/05 - 20050272637 - Compositions and methods for modulating signaling mediated by igf-1 receptor and erbb receptors The binding interactions between herstatin, or the intron 8-encoded receptor binding domain (RBD Int8) thereof, and several receptors were analyzed. According to aspects of the present invention, herstatin and the intron 8-encoded domain bind with high affinity (e.g., nM concentrations) to all four of the ErbB receptors: EGFR (HER-1, erbB-1); ... 12/08/05 - 20050272636 - Treatment and diagnosis of a reproductive disorder by measuring or inhibiting interferon-gamma The invention provides compositions and methods for diagnosing and treating reproductive disorders. The invention also provides methods for diagnosing reproductive disorders by detecting the presence of IFN-γ in the semen of a prospective father, which is indicative of the presence of a reproductive disorder. In particular, the invention provides a ... 12/08/05 - 20050272635 - Use of corticotroph-derivced glycoprotein hormone to treat liver steatosis The use of corticotrph-derived glycoprotein hormone to treatment liver steatosis, liver steatohepatitis, and cirrhosis of the liver, as well as other abnormalities in hepatic function that are related to obesity. ... 12/08/05 - 20050272634 - Use of erythropoietin The present invention relates to the use of erythropoietin for stimulating the physiological mobilization, proliferation and differentiation of endothelial progenitor cells, for stimulating vasculogenesis, for the therapy of diseases associated with a dysfunction of endothelial progenitor cells and for producing pharmaceutical compositions for the treatment of such diseases, and pharmaceutical ... 12/08/05 - 20050272633 - Derivatives of the nf-kappab inducing enzyme, their preparation and use This invention relates to the use of NIK and related molecules for the modulation of signal activities controlled by cytokines, and some new such molecules. ... 12/01/05 - 20050267014 - Pharmaceutical composition comprising factor vii polypeptides and tranexamic acid The present invention relates to compositions comprising factor VII or a factor VII-related polypeptide and tranexamic acid, and the use thereof for treating bleeding episodes. ... 12/01/05 - 20050267013 - Methods for affecting various diseases utilizing lxr compounds The present invention relates to methods for elevating high density lipoprotein (HDL) plasma levels, decreasing the absorption of dietary cholesterol in the intestine, decreasing the plasma level of low density lipoprotein (LDL), and increasing the conversion of cholesterol to bile acids, utilizing LXRβ selective agonists, usually without elevating the plasma ... 12/01/05 - 20050267012 - Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma Inhibitors of the MAPK pathway, including MEK-directed proteases and small molecule inhibitors, are cytotoxic to human melanoma cells in vitro and in vivo via apoptotic mechanisms. These compounds are used to kill melanoma cells and to treat subjects with melanoma, either alone or in combination with other therapeutic modalities. ... 12/01/05 - 20050267011 - Coupling of excitation and neurogenesis in neural stem/progenitor cells Coupling of excitation to neurogenesis in proliferating post-natal NPCs is demonstrated in vitro and in vivo. Neurogenesis is potently enhanced by excitatory stimuli, and involves Cav1.2/1.3 channels and NMDA receptors. These Ca2+ influx pathways are located on the proliferating NPCs, allowing them to directly sense and process excitatory stimuli. Excitation ... 12/01/05 - 20050267010 - Bi-lateral local renal delivery for treating congestive heart failure and for bnp therapy The invention relates to systems and methods for local renal delivery of agents to subjects that are at risk for congestive heart failure and other conditions. The invention encompasses devices for renal drug delivery and methods of use. ... 12/01/05 - 20050267009 - Method of treatment of acute and persistent pain Biochemical mediators of inflammation facilitate persistent pain disorder. Treatment follows a multilevel pain gate model to enable site-specific application of appropriate inhibitors that block receptor sites. The result often is the effective treatment of the pain disorder by the administration of lower dosages of the inhibitors than used according to ... 11/24/05 - 20050261167 - Compositions for sleeping disorders Provided herein is a composition that contains an effective amount of one or more compounds for treating, preventing, or ameliorating a disorder such as insomnia or another sleeping disorder and using the composition. ... 11/24/05 - 20050261166 - Compositions and methods for the therapy and diagnosis of lung cancer Compositions and methods for the therapy and diagnosis of cancer, particularly lung cancer, are disclosed. Illustrative compositions comprise one or more lung tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. ... 11/17/05 - 20050256033 - Methods and compositions using stearoyl-coa desaturase to identify triglyceride reducing therapeutic agents The use of screening assays based on the role of human stearoyl-CoA desaturase-1 (“hSCD1”) in human diseases, disorders or conditions relating to serum levels of triglyceride, VLDL, HDL, LDL, total cholesterol, or production of secretions from mucous membranes, monounsaturated fatty acids, wax esters, and the like, is disclosed. Also disclosed ... 11/17/05 - 20050256032 - Polyoxyalkylene compound and method for making A process for forming a conjugate of a polyoxyalkylene polymer, such as polyethylene glycol, with a compound containing an amine group(s) and/or a sulfide group(s) by reacting the compound with an acrylate terminated polyoxyalkylene, such as polyethylene glycol terminated at one end with acrylate or methacrylate and terminated at the ... 11/17/05 - 20050256031 - Composition for relieving discomfort The invention relates to a method of controlling feelings of pain in infants or diseased or elderly persons using a complete nutrition or a nutritional supplement. The method comprises administering increased levels of folic acid, vitamin B6 and vitamin B12 or their functional equivalents. ... 11/17/05 - 20050256030 - Heterocyclic self-immolative linkers and conjugates The present invention provides heterocyclic linker compounds useful for linking drug moieties to ligands. The compounds also include drug-ligand conjugates comprising a ligand capable of targeting a selected cell population, and a drug connected to the ligand by a heterocyclic linker moiety. The linker moiety comprises a peptide sequence that ... 11/17/05 - 20050256029 - Methods and compositions for alleviating stuttering Methods of treating stuttering include treating people with gamma-aminobutyric acid (GABA) receptor modulators, including cyclopyrrolones. A second active agent may be used with GABA receptor modulators. Active enantiomers, active metabolites, and pharmaceutically acceptable salts of gamma-aminobutyric acid receptor modulators, including cyclopyrrolones, are acceptable components of the compositions. The cyclopyrrolone class ... 11/17/05 - 20050256028 - Treatment of conditions through modulation of the autonomic nervous system during at least one predetermined menstrual cycle phase Methods are provided for treating a subject for a condition. In accordance with the subject methods, at least a portion of a subject's autonomic nervous system is modulated during at least one predetermined phase of the subject's menstrual cycle to alter the parasympathetic activity/sympathetic activity ratio in a manner that ... 11/10/05 - 20050250675 - Antitumor agents wherein R1, R2, R3, R4, R5, R6, and R7 have any of the values defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising compounds of formula I or II, intermediates and processes useful for preparing compounds of formula I or II, and methods comprising ... 11/10/05 - 20050250674 - Nutritional and food supplement preparation comprising creatine and orotic acid complexes, derivatives and analogs The present invention provides nutritional, pharmaceutical, or dietetic preparations that comprise creatine and orotic acid derivatives, creatine-orotic acid complexes and derivatives thereof, and functional analogs of such compounds and compositions, and the use of these compounds and compositions in the treatment of enhanced body performance of humans and animals, or ... 11/10/05 - 20050250673 - Neurodegenerative disease treatment A method of identifying a 5′AMP-activated protein kinase inhibitor for treating a neurodegenerative disease. Disclosed are a method and a packaged product for treating a neurodegenerative disease. Also disclosed is a method for treating a 5′AMP-activated protein kinase-related disease and a related packaged product. ... 11/03/05 - 20050245432 - N-methyl amino acids The present invention relates to a compound of formula (I) or (II), processes for preparing them, peptides including them and kits involving them. ... 11/03/05 - 20050245431 - Membrane, device and method for removing proteases from liquids The invention comprises a membrane and device and method for removing proteases from fluids, particularly from biological fluids and pharmaceutical solutions, which uses a microporous membrane body, whereby inhibitors that selectively bind proteases are coupled to the membrane body by chemically activated groups. ... 10/27/05 - 20050239685 - Tissue volume reduction Devices, compositions, and methods for achieving non-surgical lung volume reduction (e.g., bronchoscopic lung volume reduction (BLVR)) are described. BLVR can be carried out by collapsing a region of the lung, adhering one portion of the collapsed region to another, and promoting fibrosis in or around the adherent tissue. ... 10/27/05 - 20050239684 - Compounds which inhibit beta-secretase activity and methods of use thereof The present invention provides novel beta-secretase inhibitors and methods for their use, including methods of treating of Alzheimer's disease. ... 10/20/05 - 20050233944 - Arginine compositions for coordinate modification of multiple cardiovascular risk factors The present invention relates generally to compositions and methods for coordinate reduction of the serum levels of cardiovascular arterial disease risk factors, such as total cholesterol, LDL cholesterol, HDL/LDL ratio, triglycerides, homocysteine, and C-reactive protein. The composition comprises an arginine compound and another member selected from high molecular weight aliphatic ... 10/20/05 - 20050233943 - Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases Peptide conjugates in which cytocidal and cytostatic agents, such as polyamine analogs or naphthoquinones, are conjugated to a polypeptide recognized and cleaved by enzymes such as prostate-specific antigen (PSA) and cathepsin B are provided, as well as compositions comprising these conjugates. Methods of using these conjugates in the treatment of ... 10/20/05 - 20050233942 - Oxygenated dibenzo-alpha-pyrone chromoproteins A composition of oxygenated dibenzo-alpha-pyrone chromoproteins (DCP) and their isolation from shilajit, fossils of ammonites, corals and other invertebrates. More particularly, to the description of DCP-composition comprising oxygenated dibenzo-alpha-pyrone or its conjugates, phosphocreatine, proteins, fatty acyl esters of glycerol and other small ligands, e.g., carotenoids, sterols and aromatic acids, as ... 10/20/05 - 20050233941 - Pin coated assay A method for identifying an agent that has an influence on the amount of an analyte expressed by a cell, said method comprising stimulating a cell to produce at least 2 analytes, forming, in the absence and in the presence of a candidate compound, on the pins of a matrix ... 10/13/05 - 20050227911 - Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules The present invention provides hydrophilic dispersions comprising nanoparticles of inclusion complexes consisting essentially of nanosized particles of a macromolecule wrapped in an amphiphilic polymer such that non-valent bonds are formed between the macromolecule and the amphiphilic polymer. The macromolecules may be a naturally-occurring, synthetic or recombinant polypeptide, protein, polysaccharide or ... 10/13/05 - 20050227910 - Local regional chemotherapy and radiotherapy using in situ hydrogel Methods regarding local regional treatment in situ for an individual, such as of a tumor, are provided herein. A hydrogel composition is generated in situ in the tumor by administering a polymer, such as a polysaccharide or a polyamino acid, with a therapeutic agent, such as a radionuclide or a ... 09/08/05 - 20050197280 - Antioxidant combination composition and use thereof (d) coenzyme Q10; (e) Vitamin E: and (i) selenomethionine, suitable for counteracting oxidative stress and use thereof are disclosed. ... 09/01/05 - 20050192210 - Compositions and methods for treating diseases This invention relates to compositions and methods for treatment of vascular conditions. The invention provides arginine polymers and arginine homopolymers for the treatment and/or prevention of glaucoma, pulmonary hypertension, asthma, chronic obstructive pulmonary disease, erectile dysfunction, Raynaud's syndrome, heparin overdose, vulvodynia, and wound healing. The invention also provides arginine polymers ... 09/01/05 - 20050192209 - Eosinophil major basic protein as a natural heparanase-inhibiting protein, compositions, methods and uses thereof The use of a eosinophil secondary granules basic protein and any functional fragments thereof, and preferably, the use of Major Basic Protein (MBP) purified from eosinophils, as a natural heparanase inhibitor. Also, methods for the inhibition of the catalytic activity of heparanase using MBP, and to methods and compositions for ... 08/25/05 - 20050187141 - Control of gene induced by oxidated lipids in human artery wall cells This invention provides novel methods of inhibiting one or more symptoms of atherosclerosis. Also provided are assays for compounds that will inhibit the progression and/or ameliorate one or more symptoms of atherosclerosis. The methods and assays are based, in part, on the discovery that oxidized LDL or components thereof induce ... 08/25/05 - 20050187140 - Polymer compositions and methods for their use Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss. ... 08/25/05 - 20050187139 - Albumin-based colloid composition having at least one protected thiol region, methods of making, and methods of use A composition comprising an albumin-based colloid composition having at least one protected thiol region, method of making the same, and method for use, including treating hypovolemic conditions such as capillary leak syndrome and shock, are disclosed. ... 08/25/05 - 20050187138 - Peptide beta-strand mimics based on pyridinones, pyrazinones, pyridazinones, and triazinones Peptide analogs in which one or more amino acids is replaced by a diaza- or triazacyclohexenone, or by an aza-, diaza-, or triazacyclohexenone that is substituted at the α-position with a side chain of an amino acid, display an improved ability to assume a β-strand conformation and to enter into ... 08/18/05 - 20050181983 - Treatment of shock using adrenomedullin binding protein-1 Methods of treating a mammal in shock or at risk for shock are provided. The methods involve administration of an adrenomedullin binding protein-1 to the mammal. Also provided are methods of preventing or treating a physiologic effect of shock in a mammal. These methods also involve administration of an adrenomedullin ... 08/18/05 - 20050181982 - Crystal structures of anti-factor ix fab fragments and methods of use for peptidomimetic design Novel anti-Factor IX Fab fragment crystalline structures are identified. Methods of identifying peptidomimetics of these fragments are disclosed ... 08/18/05 - 20050181981 - Method of treatment The present invention relates generally to a method of treatment and in particular a method of treating disorders of the nervous system such as arising from or during disease or injury. The method of the present invention involves manipulating expression of Eph receptors or their functional equivalents to increase or ... 08/18/05 - 20050181980 - Novel non-selective cation channel in neural cells and method for treating brain swelling A composition comprising a novel Ca2+-activated, [ATP]i-sensitive nonspecific cation (NCCa-ATP) channel is described. The channel is found in mammalian neural cells and exhibits a different sensitivity to block by various adenine nucleotides, and is activated by submicromolar [Ca]i. The NCCa-ATP channel is activated under conditions of ATP depletion, which causes ... 08/18/05 - 20050181979 - Vascular endothelial growth factor-2 The present invention is directed to VEGF-2 polynucleotides and polypeptides and methods of using such polynucleotides and polypeptides. In particular, provided are methods of treating retinal disorders with VEGF-2 polynucleotides and polypeptides. ... 08/18/05 - 20050181978 - Therapeutic use of factor xi The present invention provides methods and compositions for treating bleeding episodes. The methods are carried out by administering to a patient in need thereof a preparation comprising a factor XI polypeptide, in an amount effective for such treatment. The methods of the invention result in one or more of: reduced ... 08/18/05 - 20050181977 - Medical implants and anti-scarring agents Implants are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal. The agent may be any suitable anti-scarring agent, e.g., a cell cycle inhibitor, and may be used in conjunction with a second pharmaceutical agent, ... 08/18/05 - 20050181976 - Amphiphilic oligomers A therapeutic formulation comprising a microemulsion of a therapeutic agent in free and/or conjugatively coupled form, wherein the microemulsion comprises a water-in-oil (w/o) microemulsion including a lipophilic phase and a hydrophilic phase, and has a hydrophilic and lipophilic balance (HLB) value between 3 and 7, wherein the therapeutic agent may ... 08/18/05 - 20050181975 - Crystal structure of fms-like tyrosine kinase The invention relates to FMS-like tyrosine kinase (FLT3), FLT3 binding pockets or FLT3-like binding pockets. The invention relates to a computer comprising a data storage medium encoded with the structure coordinates of such binding pockets. The invention also relates to methods of using the structure coordinates to solve the structure ... 08/18/05 - 20050181974 - Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists This invention relates to a method for selectively enhancing the analgesic potency of a bimodally-acting opioid agonist such as morphine and simultaneously attenuating anti-analgesia, hyperalgesia, hyperexcitability, physical dependence and/or tolerance effects associated with the administration of the bimodally-acting opioid agonist. The method of the present invention comprises administering to a ... 08/18/05 - 20050181973 - Self-assembling peptides incorporating modifications and methods of use thereof The invention provides a self-assembling peptide comprising (a) a first amino acid domain that mediates self-assembly, wherein the domain comprises alternating hydrophobic and hydrophilic amino acids that are complementary and structurally compatible and self-assemble into a macroscopic structure when present in unmodified form; and (b) a second amino acid domain ... 08/18/05 - 20050181972 - Modification of the properties of a fibrin matrix with respect to growth and ingrowth of cells A method for modifying the properties of a fibrin matrix relative to growth and ingrowth of cells, wherein for forming the fibrin matrix a fibrinogen is used consisting of a selected fibrinogen variant or a fibrinogen enriched or depleted in a selected fibrinogen variant. In particular, the use of high-molecular ... 08/18/05 - 20050181971 - Treatment of type i diabetes mellitus Use of a growth hormone antagonist to reduce the overnight insulin requirement of a patient suffering from Type I diabetes mellitus or from dawn phenomenon. ... 08/11/05 - 20050176623 - Non-invasive treatment of disease using amphipathic compounds The present invention features a non-invasive system and method for delivering apolipoprotein, amphipathic compounds, and the like into the blood stream using pulmonary delivering. Apolipoprotein, amphipathic compounds, and the like is suspended in a solvent, preferably a saline solution. Next, the soluation is nebulized to form a plurality of droplets ... 08/11/05 - 20050176622 - Secondary binding site of dipeptidyl peptidase iv (dpiv) The present application relates to the secondary binding site of dipeptidyl peptidase IV, its relationship amongst substrates and to the modulation of substrate specificity of dipeptidyl peptidase IV (DP IV, synonym: DPP IV, CD26, EC 3.4.14.5). The application relates further to compounds that bind to the secondary binding site of ... 08/11/05 - 20050176621 - Crystalline compositions for controlling blood glucose The present invention relates to insulin crystals formed from zinc, protamine, a hexamer-stabilizing compound, and a polypeptide selected from the group consisting of insulin, an insulin analog, and a derivatized insulin. The crystals are suitable for administering to a patient for control of blood glucose levels. The crystals have been ... 08/11/05 - 20050176620 - Crosslinked compounds and methods of making and using thereof Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) the oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one tbiol compound with at least one thiol-reactive compound. ... 08/04/05 - 20050171007 - Therapeutic method This invention is directed to new therapeutic uses which involve the stimulation of chondrocyte prloliferation. More particularly, it is directed to the use of amylin and adrenomedullin as agents which stimulate chrondrocyte proliferation and which therefore have utility in the treatment of cartilage disorders and/or cartilage mediated bone growth. ... 08/04/05 - 20050171006 - Treatment of congestive heart failure A mammal with congestive heart failure is treated by administering to the mammal an effective amount of growth hormone. Treatment results in increased left ventricular cystolic pressure, increased left ventricular maximum, increased cardiac output, and increased stroke volume index. Treatment also results in reduced left ventricular end-diastolic pressure and reduced ... 08/04/05 - 20050171005 - Methods and compositions for modulating beta-catenin phosphorylation The present invention provides modulators of β-catenin phosphorylation. More specifically, the present invention provides inhibitors and enhancers of β-catenin Serine 45 (S45) phosphorylation. Examples of inhibitors provided by the invention are the proteins Dishevelled (Dvl), Wnt, phosphatase PP2A and CKI7. Examples of enhancers of beta-catenin phosphorylation are phosphatase inhibitors and ... 08/04/05 - 20050171004 - Use of cardiotrophin-1 to promote wound healing and counteract overt fibrosis The use of CT-1, bioactive fragments thereof and mimetics thereof in promoting wound healing is described herein. ... 08/04/05 - 20050171003 - Use of a growth hormone or a growth hormone secretagogue for appetite-suppression or induction of satiety Use of growth hormone for appetite suppression or satiety induction ... 08/04/05 - 20050171002 - Polyoxyalkylene compound and method for making A process for forming a conjugate of a polyoxyalkylene polymer (such as polyethylene glycol) with a compound containing an amine group(s) and/or a sulfide group(s) by reacting the compound with an acrylate terminated polyoxyalkylene (such as polyethylene glycol terminate at one end with acrlyate or methacrylate and terminated at the ... 08/04/05 - 20050171001 - Hemostatic compositions and devices The present invention includes both sterilized and unsterilized hemostatic compositions that contain a biocompatible liquid having particles of a biocompatible polymer suitable for use in hemostasis and which is substantially insoluble in the liquid, up to about 20 percent by weight of glycerol and about 1 percent by weight of ... 08/04/05 - 20050171000 - Three dimensional coordinates of melanocortin-4 receptors Three-dimensional coordinates of melanocortin-4 receptors are useful in computer aided drug design. ... 07/28/05 - 20050164912 - Methods for recovering cleaved peptide from a support after solid phase synthesis Methods for the solid phase synthesis of peptides and peptide intermediates, in particular methods involving recovering peptides from resin supports at excellent yield. In this invention, an alternating at least partially repeating cycle of shrinking and swelling treatments are used. Each shrinking or swelling part of a cycle may involve ... 07/28/05 - 20050164911 - Unifying mechanism and methods to prevent cancer and neurodegenerative diseases The present invention relates to methods for preventing the development of cancer or neurodegenerative diseases by administering N-Acetylcysteine (NAC), melatonin, or a combination thereof. The present invention also relates to methods for diagnosing cancer and/or neurdegenerative disease by detecting or determining the amount of dopamine metabolites, 4-CE, 2-CE, methylation of ... 07/28/05 - 20050164910 - Non-antigenic stabilizer and physiologically active substance The nonantigenic stabilizer contains not less than 70% of peptides which can be obtained by specifically decomposing relatin or collagen using a collagenase that have a molecular weight not more than 20,000 and an amino acid sequence (Gly-x-Y)n. The physiologically active substance contains 0.005-15 percent by weight of the nonantigenic ... 07/28/05 - 20050164909 - Methods and reagents for treating inflammation and fibrosis Methods are provided for providing anti-inflammatory activity and inhibiting a fibrotic disease, such as pulmonary fibrosis, in an individual. The methods comprise administering a biologically effective amount of latency-associated peptide (LAP) to the individual. Also provided are pharmaceutical compositions comprising LAP for use in accordance with these methods. ... 07/28/05 - 20050164908 - Neuroprotective complex for treatment of cerebral ischemia and injury The invention provides a pharmaceutical composition useful in treating cerebral ischemia and cerebral injury. The pharmaceutical composition is also useful as a prophylactic treatment during surgical procedures wherein the potential for ischemic tissue damage is present. Also included in the invention is a method for preparing the pharmaceutical composition, as ... 07/28/05 - 20050164907 - Diagnosis and treatment of glaucoma and methods for discovering new glaucoma therapeutic agents based on the wnt/planar cell polarity (pcp) signaling pathway The present invention provides methods for diagnosing and treating glaucoma and identifying agents potentially useful for treating glaucoma. The invention further provides compositions useful for treating glaucoma. ... 07/28/05 - 20050164906 - Novel raf/ras binding compounds The invention provides novel means to inhibit the Mitogen Activated Protein Kinases (MAPKs) pathway activated by Ras/Raf complex using GILZ protein related compounds as inhibitors of Raf/Ras-mediated signal transduction. Pharmaceutical compositions containing such compounds are also disclosed. ... 07/21/05 - 20050159338 - Method for inhibiting the formation of seromas using factor xiii Use of factor XIII for inhibiting the formation of seromas by administering factor XIII. The factor XIII can be administered locally at the site of a wound or surgery or administered systemically. If the factor XIII is administered locally, it can be activated or non-activated and may be administered in ... 07/21/05 - 20050159337 - Use of botulinum toxin therapy for treatment of overactive bladder The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. ... 07/21/05 - 20050159336 - Use of copolymer 1 and related peptides and polypeptides and t cells treated therewith for neuroprotective therapy Methods are provided for treating injury to or disease of the central or peripheral nervous system. In one embodiment, treatment is effected by administering activated T cells that recognize an antigen of Cop 1 or a Cop 1-related peptide or polypeptide to promote nerve regeneration or to prevent or inhibit ... 07/21/05 - 20050159335 - Pharmaceutical administration form for peptides, process for its preparation, and use A method for preventing aggregation of an LHRH antagonist in a pharmaceutical composition. The method comprises combining the LHRH antagonist in the form of an acetate, gluconate, glucuronate, lactate, citrate, ascorbate, benzoate or phosphate salt at least one of the acids for forming the salts in free acid form. ... 07/21/05 - 20050159334 - Method for treating rheumatoid arthritis by inhibiting peptidylarginine deiminase Rheumatoid arthritis is treated with the administration of a therapeutic dose of a therapeutically acceptable PAD inhibitor. Administration can occur after the onset of RA symptoms, or prophylactically before such symptoms present. In one embodiment, the inhibitor has a side chain including a benzamide group to the left and an ... 07/21/05 - 20050159333 - Methods of modulating smooth muscle contractility Method for modulating bladder smooth muscle contractility comprising the step of contacting a polypeptide in a ROCK pathway with a compound that modulates an activity of said polypeptide. ... 07/21/05 - 20050159332 - Ntb-a,a a surface molecule involved in natural killer cellss activity The present invention relates to a novel protein, termed NTB-A, nucleic acid molecules encoding the same and uses thereof. The invention also relates to methods of regulating Natural Killer cells activity by regulating the activity of NTBA-A in vitro, ex vivo or in vivo. The invention also comprises methods of ... 07/14/05 - 20050153873 - Frequency assisted transdermal agent delivery method and system An apparatus and method for transdermally delivering a biologically active agent comprising a delivery system having a microprojection member (or system) that includes a plurality of microprojections (or array thereof) that are adapted to pierce through the stratum corneum into the underlying epidermis layer, or epidermis and dermis layers, a ... 07/14/05 - 20050153872 - Methods and compositions for the treatment of infection The invention described herein provides novel compositions and methods for treating infection caused by, for example, bacteria, fungi, or virus. ... 07/14/05 - 20050153871 - Use of 20-hete synthesizing enzyme inhibitors as therapy for cerebral vascular disease A method for treating cerebral vascular diseases in a human or non-human animal is disclosed. The method involves inhibiting 20-HETE synthesizing enzyme activity sufficiently to increase or prevent a decrease in cerebral blood flow in the human or non-human animal. ... 07/07/05 - 20050148496 - Treatment of rheumatoid arthritis with hypoxia inducible factor-1alpha antagonists The invention encompasses a novel method of treating inflammatory disease, such as rheumatoid arthritis, and novel methods of identifying and screening for drugs useful in the treatment of inflammatory diseases and their clinical symptoms. The inventors have made the discovery that the activity of HIF-1α, a transcription regulator known to ... 07/07/05 - 20050148495 - Methods and materials including for treating acne The present invention provides novel methods and materials including for treating acne and including methods comprising administering to a subject a composition comprising a therapeutically effective amount of XMP.629 or a pharmaceutically acceptable salt or derivative thereof. ... 07/07/05 - 20050148494 - Methods and compositions for controlling appetite and modulating insulin sensitivity The invention features methods of enhancing whole body insulin sensitivity by modulating the endoplasmic reticulum (ER) stress response pathway in adipose cells. In one aspect, the methods involve targeting chaperone proteins important in the ER stress response pathway, for example, BiP and ERO-1. Another aspect features targeting the upstream transcription ... 06/30/05 - 20050143289 - Botulinum toxin pharmaceutical composition A botulinum toxin pharmaceutical formulation free of animal derived proteins, comprising a botulinum toxin and a recombinant albumin, suitable for therapeutic administration to a human patient, and methods for treating patients with various diseases and afflictions with the formulation. ... 06/30/05 - 20050143288 - Use of lipid conjugates in the treatment of diseases This invention provides a method of treating a subject suffering from an obstructive respiratory disease, including the step of administering to a subject a compound comprising a lipid or phospholipid moiety bound to a physiologically acceptable monomer, dimer, oligomer, or polymer, and/or a pharmaceutically acceptable salt or a pharmaceutical product ... 06/30/05 - 20050143287 - Primate prokineticin and prokineticin receptor polypeptides, related compositions and methods The invention provides an isolated squirrel monkey prokineticin receptor 2 (PKR2) polypeptide containing the amino acid sequence referenced as SEQ ID NO:2. The invention also provides an isolated chimpanzee PKR2 containing the amino acid sequence referenced as SEQ ID NO:4. Also provided are methods of identifying PKR2 agonists and antagonists ... 06/30/05 - 20050143286 - Methods of inhibiting and treating bacterial biofilms by metal chelators The invention presented herein provides methods and compositions for the prevention and treatment of bacterial infections. The methods are based on the discovery that depletion of bioavailable iron stimulates surface motility in bacteria thus inhibiting the ability of a bacterial population to develop into a biofilm. ... 06/30/05 - 20050143285 - Acetylcholine binding protein, and methods of identifying agents that modulate acetylcholine receptor activity Fluorescence based screening assays are provided that allow for the for identification of agents that selectively bind to a ligand-gated ion channel (LGIC) such as a nicotinic acetylcholine receptor (nAChR). Also provided are methods for identifying agents that selectively bind to a neuronal-type nAChR by detecting binding of the agent ... 06/30/05 - 20050143284 - Vaccination The present invention relates to improvements in DNA vaccination and in particular, methods of vaccinating a mammal against disease states, and to the use of imidazo[4,5, -c]-4-amine derivative adjuvants in the manufacture of medicaments for boosting previously vaccinated individuals. ... 06/30/05 - 20050143283 - Activated protein c formulations The invention relates to pharmaccutical compositions of activated protein C with a chelating agent. Preferably, the formulation contains activated protein C, a chelating agent, a bulking agent, a buffer, and/or a salt with a reconstituted pH between about 5.5 5 and about 6.5. Alternatively, the chelating agent is added to ... 06/23/05 - 20050137124 - Agents for intravitreal administration to treat or prevent disorders of the eye Methods and preparations for treating disorders of the eye and/or causing posterior vitreous disconnection or disinsertion. Preparations containing a) urea, b) urea derivatives (e.g., hydroxyurea, thiourea), c) a non-steroidal anti-inflamatory agents, d) antmetabolites, e) urea, urea derivatives, non-enzymatic proteins, nucleosides, nucleotides and their derivatives (e.g., adenine, adenosine, cytosine, cytadine, guanine, ... 06/23/05 - 20050137123 - Use of agents that down-regulate expression of tanis and/or p21^waf1/cip1/sd1 genes, and use of agents that inhibit, degrade, sequester or prevent the neurotoxicity of gene product proteins of tanis and p21^waf1/cip1/sd1 genes The present invention provides compositions and methods for treating glaucoma, ocular hypertension, and age-related macular degeneration. More specifically, the present invention describes the use of agents that down-regulate expression of tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the eye. ... 06/23/05 - 20050137122 - Use of agents that prevent generation of amyloid and amyloid-like lipoproteins, and/or use of agents that promote sequestration and/or degradation of, and/or prevent neurotoxicity of such proteins in the treatment of hearing loss and improving body balanc The present invention provides compositions and methods for treating otic disorders. More specifically, the present invention describes the use of agents that down-regulate expression of Tanis and/or p21Waf1/Cip1/Sd1 genes to treat such disorders of the ear. ... 06/23/05 - 20050137121 - Inhibition of invasive remodelling Invasive remodelling in a mammal may be inhibited by (1) inhibiting or abolishing the protein cleaving action of plasmin and (2) inhibiting or abolishing the protein cleaving action of at least one additional proteolytic enzyme active in invasive remodelling, such as a metalloprotease. ... 06/16/05 - 20050130879 - Modifying tissue surfaces by liquid crystal formation A method for modifying the surface properties of tissue in vivo is described. The method comprises forming a liquid crystalline matrix on the tissue surface wherein the matrix comprises a tissue surface component. In one embodiment there is provided a method for improving the bonding of surgical glues and cements ... 06/16/05 - 20050130878 - Prevention of photic injury by administering a tace inhibitor The present invention relates to is directed to methods of preventing neurodegeneration resulting from photo-oxidative stress. The methods of the invention involve inhibiting the action of the tumor necrosis factor-converting enzyme (TACE) in retinal cells that have experienced photic injury. ... 06/16/05 - 20050130877 - Axon regeneration with pkc inhibitors Regenerative growth of an adult mammalian central nervous system neuron axon subject to growth inhibition by endogenous, myelin growth repulsion factors is promoted by delivering to the axon a therapeutically effective amount of a specific inhibitor of protein kinase C, whereby regenerative growth of the axon is promoted and a ... 06/16/05 - 20050130876 - Use of substances for treating tumors The present invention relates to the use of an active ingredient and to a method for the prevention or treatment of tumors, the diagnostic detection of disorders associated with these tumors, and pharmaceutical compositions and kits related thereto. ... 06/09/05 - 20050124531 - Biological inhibitions induced by contact inhibitory factor The present invention is directed to a method for treating a patient suffering from inappropriate or excessive angio-genic activity comprising on administering to a patient in need of such treatment an amount of Contact Inhibitory Factor effective to treat said disease. Also disclosed herein are methods for preventing a cancer ... 06/02/05 - 20050119160 - Methods and reagents for the treatment of immunoinflammatory disorders The invention features a method for treating a patient diagnosed with, or at risk of developing, an immunoinflammatory disorder by administering to the patient a tetra-substituted pyrimidopyrimidine, either alone or in combination with one or more additional agents. The invention also features a composition containing a tetra-substituted pyrimidopyrimidine in combination ... 06/02/05 - 20050119159 - Remedy for ischemic heart failure In the process of extensively searching for a drug elevating the survival ratio in ischemic heart failure, in particular postinfarction heart failure, it is found out that βARKct which is a βARK1 inhibitor is efficacious not only in improving heart function but also elevating survival ratio in postinfarction heart failure. ... ### FreshPatents.com Support |